[go: up one dir, main page]

PE20180463A1 - Virus de la enteritis del pato y usos del mismo - Google Patents

Virus de la enteritis del pato y usos del mismo

Info

Publication number
PE20180463A1
PE20180463A1 PE2017002892A PE2017002892A PE20180463A1 PE 20180463 A1 PE20180463 A1 PE 20180463A1 PE 2017002892 A PE2017002892 A PE 2017002892A PE 2017002892 A PE2017002892 A PE 2017002892A PE 20180463 A1 PE20180463 A1 PE 20180463A1
Authority
PE
Peru
Prior art keywords
refers
enteritis virus
duck enteritis
virus
dev
Prior art date
Application number
PE2017002892A
Other languages
English (en)
Inventor
Saeki Yukari
Shuji Saitoh
Original Assignee
Ceva Sante Animale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceva Sante Animale filed Critical Ceva Sante Animale
Publication of PE20180463A1 publication Critical patent/PE20180463A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16361—Methods of inactivation or attenuation
    • C12N2710/16362—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se refiere a una nueva construccion del virus de la enteritis de pato (DEV), en el que dicho virus tiene un gen UL4 inactivo, el cual esta mutado, eliminado o interrumpido, y adicionalmente comprende un acido nucleico extrano localizado en el gen UL4 que codifica un antigeno o una molecula inmunoestimulante, preferentemente un antigeno de un patogeno aviar. Tambien se refiere a una celula huesped y a un metodo para producirlo o replicarlo; tambien se refiere a un kit de vacunacion. Dicho DEV se utiliza generalmente para vacunar o inmunizar aves de corral, preferiblemente pollos
PE2017002892A 2015-06-30 2016-06-29 Virus de la enteritis del pato y usos del mismo PE20180463A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15174515 2015-06-30

Publications (1)

Publication Number Publication Date
PE20180463A1 true PE20180463A1 (es) 2018-03-06

Family

ID=53496539

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002892A PE20180463A1 (es) 2015-06-30 2016-06-29 Virus de la enteritis del pato y usos del mismo

Country Status (10)

Country Link
US (5) US10202582B2 (es)
EP (1) EP3317406A1 (es)
JP (1) JP6802813B2 (es)
CN (1) CN108368488B (es)
CA (1) CA2992158C (es)
MX (1) MX381252B (es)
PE (1) PE20180463A1 (es)
RU (1) RU2721575C2 (es)
UA (1) UA122339C2 (es)
WO (1) WO2017001469A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6802813B2 (ja) * 2015-06-30 2020-12-23 セヴァ・サンテ・アニマールＣｅｖａ Ｓａｎｔｅ Ａｎｉｍａｌｅ アヒル腸炎ウイルス及びその使用
EP3263129A1 (en) * 2016-06-29 2018-01-03 Ceva Sante Animale Duck enteritis virus and the uses thereof
CN110904058B (zh) * 2018-09-14 2023-03-07 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 重组鸭瘟病毒疫苗及其构建方法和应用
JP2023520889A (ja) * 2020-03-31 2023-05-22 グレイル エルエルシー ゲノム領域モデリングによるがん分類
CN113249340B (zh) * 2020-08-19 2022-07-19 浙江省农业科学院 一株双色荧光蛋白标记鸭瘟病毒及其构建方法和应用
TW202523838A (zh) * 2023-08-25 2025-06-16 大陸商勃林格殷格翰動物保健（中國）有限公司 新型dev載體
WO2025044922A2 (en) * 2023-08-25 2025-03-06 Boehringer Ingelheim Vetmedica (China) Co., Ltd. Vectored dev avian influenza h9 vaccines
WO2025044920A2 (en) * 2023-08-25 2025-03-06 Boehringer Ingelheim Vetmedica (China) Co., Ltd. New dev vectors for avian vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757061B1 (fr) 1996-12-16 1999-03-26 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
EP2140879A1 (en) * 2001-05-09 2010-01-06 M'S Science Corporation Composition and method for treating cancer using herpes virus
FR2916759B1 (fr) * 2007-05-29 2009-07-10 Adisseo France Sas Soc Par Act Peptide rumc presentant une activite antimicrobienne
CN102277368B (zh) * 2010-06-13 2013-12-25 中国农业科学院哈尔滨兽医研究所 鸭病毒性肠炎病毒感染性重组克隆系统及构建方法和应用
CN102533674B (zh) * 2010-12-08 2014-05-14 中国农业科学院哈尔滨兽医研究所 表达禽流感病毒血凝素基因的重组鸭病毒性肠炎病毒疫苗株及其构建方法和应用
CN103667351B (zh) * 2012-09-10 2017-01-25 中国农业科学院哈尔滨兽医研究所 以鸭病毒性肠炎病毒疫苗株为载体的重组病毒疫苗在鸡形目禽类中的应用
WO2014036735A1 (zh) 2012-09-10 2014-03-13 中国农业科学院哈尔滨兽医研究所 鸭病毒性肠炎病毒疫苗株作为表达载体在制备预防鸡形目禽类疾病的重组病毒疫苗中的应用
JP6802813B2 (ja) * 2015-06-30 2020-12-23 セヴァ・サンテ・アニマールＣｅｖａ Ｓａｎｔｅ Ａｎｉｍａｌｅ アヒル腸炎ウイルス及びその使用
EP3263129A1 (en) 2016-06-29 2018-01-03 Ceva Sante Animale Duck enteritis virus and the uses thereof

Also Published As

Publication number Publication date
US20190136208A1 (en) 2019-05-09
MX2018000091A (es) 2018-02-19
WO2017001469A1 (en) 2017-01-05
UA122339C2 (uk) 2020-10-26
US10202582B2 (en) 2019-02-12
CN108368488A (zh) 2018-08-03
CA2992158C (en) 2023-11-21
JP6802813B2 (ja) 2020-12-23
CA2992158A1 (en) 2017-01-05
RU2018103145A (ru) 2019-07-30
MX381252B (es) 2025-03-11
US20180187164A1 (en) 2018-07-05
US10711255B2 (en) 2020-07-14
US20190144835A1 (en) 2019-05-16
CN108368488B (zh) 2022-04-05
JP2018519826A (ja) 2018-07-26
US10717967B2 (en) 2020-07-21
BR112017028420A2 (pt) 2018-08-28
US10704028B2 (en) 2020-07-07
RU2018103145A3 (es) 2019-11-20
RU2721575C2 (ru) 2020-05-20
US10711254B2 (en) 2020-07-14
EP3317406A1 (en) 2018-05-09
US20190144836A1 (en) 2019-05-16
US20190136209A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
PE20180463A1 (es) Virus de la enteritis del pato y usos del mismo
CY1125084T1 (el) Εμβολια νουκλεϊκου οξεος
CO2018005258A2 (es) Vacuna del virus herpes simple
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
CO2018012513A2 (es) Anticuerpos
PE20181092A1 (es) Anticuerpos anti-pd1 y metodos de uso
MX373792B (es) Coronavirus.
CO2017007105A2 (es) Nuevos virus de tilapia
MX2018011425A (es) Construcciones de anticuerpos de adn y método para utilizarlas.
PE20190397A1 (es) Virus de enteritis de pato y usos del mismo
BR112017023131A2 (pt) anticorpos anti- fcrn
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
BR112018015893A2 (pt) vacinas de câncer e métodos de tratamento usando as mesmas
PL396415A1 (pl) Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciala specyficznie rozpoznajace bialko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA
MX2019005491A (es) Anticuerpo que enlaza especificamente a cd66c y uso del mismo.
MX378857B (es) Celulas huespedes modificadas y usos de las mismas.
MX2020012649A (es) Neoantígenos especificos de tumor y métodos de uso de estos.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos
AR108801A1 (es) Constructos del virus recombinante no patogénico de la enfermedad de marek que codifican antígenos del virus de la laringotraqueítis infecciosa y del virus de la enfermedad infecciosa de la bursa
MX2017016896A (es) Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos.
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
EA201791724A1 (ru) Способ получения гонадотропина
RU2016152662A (ru) Микроорганизм рода Escherichia, продуцирующий L-триптофан, и способ продуцирования L-триптофана с использованием данного микроорганизма
CL2016001906A1 (es) Vacunas contra el reovirus aviar.